Default: Oncologist

ISSN: 1083-7159

Journal Home

Journal Guideline

Oncologist Q1 Unclaimed

AlphaMed Press United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Oncologist is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 157. It has a price of 1260 €. It has an SJR impact factor of 2,613 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

1260 €

Gold OA

-

Green OA

0 €

Non OA

Metrics

Oncologist

2,613

SJR Impact factor

157

H Index

449

Total Docs (Last Year)

705

Total Docs (3 years)

12820

Total Refs

3245

Total Cites (3 years)

580

Citable Docs (3 years)

4,94

Cites/Doc (2 years)

28,55

Ref/Doc


Best articles

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer

View more

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

View more

A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

View more

A Pilot Randomized Controlled Trial of Brief Cognitive-Behavioral Therapy for Anxiety in Patients with Terminal Cancer

View more

A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer

View more

Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials

View more

Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions

View more

Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis

View more

Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification

View more

Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study

View more

Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor-Positive Breast Cancer: A TEAM Study Analysis

View more

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma - Analysis Using Diagnostic Nodes

View more
SHOW MORE ARTICLES

Anti-Leukemia Chemotherapy of High-Risk Myelodysplastic Syndromes

View more

Appraising Adjuvant Aromatase Inhibitor Therapy

View more

Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

View more

Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients

View more

Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists

View more

Bone Loss and Fracture Risk Associated with Cancer Therapy

View more

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya

View more

Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications

View more

Cancer Disparities in the Context of Medicaid Insurance: A Comparison of Survival for Acute Myeloid Leukemia and Hodgkin's Lymphoma by Medicaid Enrollment

View more

Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer

View more

Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors

View more

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

View more

Comments

No comments ... Be the first to comment!